SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mesco Pharmaceuticals informs about outcome of board meeting

12 Nov 2021 Evaluate
Mesco Pharmaceuticals has informed that the board at its meeting held on 12th November 2021 considered and approved the Un-Audited Financial Results for Quarter ended on 30th September, 2021 as per Regulation 33(3) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 along with the Limited Review Report.

The above information is a part of company’s filings submitted to BSE.

Mesco Pharma Share Price

4.54 0.00 (0.00%)
10-Jan-2022 18:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×